Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero-Torres

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value AnalysisColby J Hyland, Flora Varghese, Christina Yau, et al.
Leukemia & Lymphoma|August 12, 2014
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignanciesAndres Forero-Torres, Nancy L Bartlett, Robert B Berryman, et al.
The Oncologist|March 16, 2019
What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and OncologistsGabrielle B Rocque, Aysha Rasool, Beverly R Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast CancerSara M Tolaney, Young-Hyuck Im, Emiliano Calvo, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Breast Cancer Research : BCR|March 5, 2021
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerErica M Stringer-Reasor, Jori E May, Eva Olariu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent studyJonathan W Friedberg, Philip Cohen, Ling Chen, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value AnalysisColby J Hyland, Flora Varghese, Christina Yau, et al.
Leukemia & Lymphoma|August 12, 2014
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignanciesAndres Forero-Torres, Nancy L Bartlett, Robert B Berryman, et al.
The Oncologist|March 16, 2019
What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and OncologistsGabrielle B Rocque, Aysha Rasool, Beverly R Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast CancerSara M Tolaney, Young-Hyuck Im, Emiliano Calvo, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Breast Cancer Research : BCR|March 5, 2021
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerErica M Stringer-Reasor, Jori E May, Eva Olariu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent studyJonathan W Friedberg, Philip Cohen, Ling Chen, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Pageof 10